Faglia, Giovanni

Decreased Receptor Binding of Biologically Inactive Thyrotropin in Central Hypothyroidism: Effect of Treatment with Thyrotropin-Releasing Hormone

Beck-Peccoz, P., Amr, S., Menezes-Ferreira, M. M., Faglia, G., & Weintraub, B. D. (1985) · New England Journal of Medicine

Thyroid Disorders and TreatmentsGrowth Hormone and Insulin-like Growth Factors

Cited by 261

Thyrotropin secretion in patients with central hypothyroidism: Evidence for reduced biological activity of immunoreactive thyrotropin

FAGLIA, G., BITENSKY, L., PINCHERA, A., FERRARI, C., PARACCHI, A., BECK-PECCOZ, P., AMBROSI, B., & SPADA, A. (1979) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsPituitary Gland Disorders and Treatments

Cited by 197

Abnormalities of endocrine function in patients with clinically silent adrenal masses.

Ambrosi, B., Peverelli, S., Passini, E., Re, T., Ferrario, R., Colombo, P., Sartorio, A., & Faglia, G. (1995) · European Journal of Endocrinology

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 136

The clinical impact of the thyrotropin-releasing hormone test

FAGLIA, G. (1998) · Thyroid

Thyroid Disorders and TreatmentsPituitary Gland Disorders and Treatments

Cited by 91

Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin

Persani, L., Tonacchera, M., Beck-Peccoz, P., Vitti, P., Mammoli, C., Chiovato, L., Elisei, R., Faglia, G., Ludgate, M., Vassart, G., et al. (1993) · Journal of Endocrinological Investigation

Thyroid Disorders and TreatmentsClinical Laboratory Practices and Quality Control

Cited by 45

Should dopamine agonist treatment for prolactinomas be life‐long?

Faglia, G. (1991) · Clinical Endocrinology

Pituitary Gland Disorders and TreatmentsNeuroendocrine Tumor Research Advances

Cited by 25